Radiomics vs radiologist in bladder and renal cancer. Results from a systematic review
作者：
Tramanzoli P.
Castellani D.
De Stefano V.
Brocca C.
Nedbal C.
Chiacchio G.
Galosi A. B.
Da Silva R. D.
Teoh J. Y. C.
Tiong H. Y.
Naik N.
Somani B. K.
Gauhar V.
作者单位：
Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: urobhavan@gmail.com. Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain. Department of Urology, Centro Hospital Universitário S. João, Porto, University of Porto, Porto, Portugal. Department of Urology, Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford, UK. Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic. Department of Urology, Zuyderland Medical Center, Sittard-Geleen-Heerlen, The Netherlands. Department of Medicine, Health Science Centre, McMaster University, Hamilton, ON, Canada. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
Michael G. DeGroote Cochrane Canada Centre, McMaster University, Hamilton, ON, Canada. Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Department of Urology, Royal Surrey County Hospital, Guildford, UK. Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
归属分类：
膀胱肿瘤诊断证据
DOI：
10.1097/MD.0000000000030893
关键词：
Humans
*Urinary Bladder Neoplasms/surgery/pathology
Urologic Surgical Procedures
Cystectomy
*Laser Therapy
*Lasers
Solid-State/therapeutic use
Turbt
bladder tumor
laser resection
recurrence
Introduction Radiomics in uro-oncology is a rapidly evolving science proving to be a novel approach for optimizing the analysis of massive data from medical images to provide auxiliary guidance in clinical issues. This scoping review aimed to identify key aspects wherein radiomics can potentially improve the accuracy of diagnosis, staging, and grading of renal and bladder cancer.Material and methods A literature search was performed in June 2022 using PubMed, Embase, and Cochrane Central Controlled Register of Trials. Studies were included if radiomics were compared with radiological reports only.Results Twenty-two papers were included, 4 were pertinent to bladder cancer, and 18 to renal cancer. Radiomics outperforms the visual assessment by radiologists in contrast-enhanced computed tomography (CECT) to predict muscle invasion but are equivalent to CT reporting by radiologists in predicting lymph node metastasis. Magnetic resonance imaging (MRI) radiomics outperforms radiological reporting for lymph node metastasis. Radiomics perform better than radiologists reporting the probability of renal cell carcinoma, improving interreader concordance and performance. Radiomics also helps to determine differences in types of renal pathology and between malignant lesions from their benign counterparts. Radiomics can be helpful to establish a model for differentiating low-grade from highgrade clear cell renal cancer with high accuracy just from contrast-enhanced CT scans.Conclusions Our review shows that radiomic models outperform individual reports by radiologists by their ability to incorporate many more complex radiological features.